2018 International Congress

Saturday, October 6, 2018

1:45pm-3:15pm

SURE-PD3 Trial Participant Features prior to Randomization

E. Macklin, A. Videnovic, C. Lungu, C. Kamp, C. Casaceli, D. Oakes, A. Ascherio, M. Schwarzschild; on behalf of the Parkinson Study Group SURE-PD3_Investigators (Boston, MA, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

V. Kumar (Allahabad, India)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Surgery-, hardware – and chronic stimulation-related adverse events following subthalamic nucleus deep brain stimulation for Parkinson’s disease

B. Gonenli Kocer, E. Ozturk, S. Comoglu, M. Sorar, H. Kertmen (Ankara, Turkey)

Surgical Therapy: Parkinson's Disease  ·  Hall 3FG

1:45pm-3:15pm

Swimming in PD patients with STN-DBS: A pilot exploratory study

D. Flisar, S. Ibrulj, M. Trošt, M. Benedičič, P. Mušič, S. Korelc, K. Groleger Sršen (Ljubljana, Slovenia)

Surgical Therapy: Parkinson's Disease  ·  Hall 3FG

1:45pm-3:15pm

Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study

O. Fabregues, E. Tolosa, J. Ferreira, A. Lees, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study

R. Ehret, J. Ferreira, F. Stocchi, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Berlin, Germany)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Symptom specified target and procedure selection for Parkinson’s disease: A case report

W. Linbin, L. Dianyou, P. Yixin, Z. chencheng, S. Bomin (Shanghai, China)

Surgical Therapy: Parkinson's Disease  ·  Hall 3FG

1:45pm-3:15pm

SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results

H. Fernandez (Cleveland, OH, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Tardive Myoclonus: A Case Report

S. Gazioglu, F. Civil Arslan, V. Altunayoglu Cakmak, M. Korucuk, M. Ozmenoglu (Trabzon, Turkey)

Drug-Induced Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Targeted Next Generation Sequencing in Diagnosis of Dystonia Patients

J. Ma, X.H. Wan (Beijing, China)

Genetics (Non-PD)  ·  Hall 3FG